- Conditions
- Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma
- Interventions
- AFM13, AB-101, Cyclophosphamide, Fludarabine, Interleukin-2
- Drug
- Lead sponsor
- Affimed GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Duarte, California • Orange, California + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Rheumatoid Arthritis, Pemphigus Vulgaris, Granulomatosis With Polyangiitis, Systemic Lupus Erythematosus
- Interventions
- AB-101, Rituximab, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- IRIS Research and Development, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Plantation, Florida
- Conditions
- Sexual Dysfunction, Sexual Arousal Disorder, Sexual Dysfunction, Physiological, Breast Cancer, Nipple Disorder, Neuropathy, Cancer of Breast
- Interventions
- AB-101, Placebo
- Drug
- Lead sponsor
- Applied Biology, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus, SLE
- Interventions
- AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab
- Drug
- Lead sponsor
- Artiva Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Tucson, Arizona • San Diego, California + 6 more
- Conditions
- Non Hodgkin Lymphoma
- Interventions
- AB-101, Rituximab, Interleukin-2, Cyclophosphamide, Fludarabine, Bendamustine
- Drug
- Lead sponsor
- Artiva Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Orange, California + 17 more